Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

<p>Supplemental Figures 1 - 5</p>

Պահպանված է:

Մատենագիտական մանրամասներ
Հիմնական հեղինակ:	Timothy P. DiPeri (16384177) (author)
Այլ հեղինակներ:	Kurt W. Evans (16384180) (author), Maria Gabriela Raso (15107821) (author), Ming Zhao (16384183) (author), Yasmeen Q. Rizvi (16384186) (author), Xiaofeng Zheng (16384189) (author), Bailiang Wang (16384192) (author), Bryce P. Kirby (16384195) (author), Kathleen Kong (16384198) (author), Michael Kahle (16384201) (author), Timothy A. Yap (15028749) (author), Ecaterina E. Dumbrava (16384204) (author), Jaffer A. Ajani (11016306) (author), Siqing Fu (15047712) (author), Khandan Keyomarsi (14958560) (author), Funda Meric-Bernstam (10258780) (author)
Հրապարակվել է:	2025
Խորագրեր:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology DNA Damage and Repair Gastrointestinal Cancers Preclinical Models Translational Research
Ցուցիչներ:	Ավելացրեք ցուցիչ Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!

Նմանատիպ նյութեր

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
‌: Sheheryar Kabraji (15050565)
Հրապարակվել է: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
‌: Nigel Bundred (15046233)
Հրապարակվել է: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
‌: Nigel Bundred (15046233)
Հրապարակվել է: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
‌: Nigel Bundred (15046233)
Հրապարակվել է: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
‌: Jamunarani Veeraraghavan (16461809)
Հրապարակվել է: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
‌: Jamunarani Veeraraghavan (16461809)
Հրապարակվել է: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
‌: Jamunarani Veeraraghavan (16461809)
Հրապարակվել է: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
‌: Jamunarani Veeraraghavan (16461809)
Հրապարակվել է: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
‌: Jamunarani Veeraraghavan (16461809)
Հրապարակվել է: (2025)

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
‌: Jamunarani Veeraraghavan (16461809)
Հրապարակվել է: (2025)

Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
‌: Javier Pascual (15018176)
Հրապարակվել է: (2025)

Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
‌: Sebastian Johannes Schober (14971891)
Հրապարակվել է: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
‌: Nigel Bundred (15046233)
Հրապարակվել է: (2025)

Supplemental Figure S2 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
‌: Jennifer L. Cotton (17315204)
Հրապարակվել է: (2025)

Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
‌: Javier Pascual (15018176)
Հրապարակվել է: (2025)

Supplementary Figure S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
‌: Javier Pascual (15018176)
Հրապարակվել է: (2025)

Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
‌: Javier Pascual (15018176)
Հրապարակվել է: (2025)

Supplementary Figure S5 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
‌: Javier Pascual (15018176)
Հրապարակվել է: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
‌: Milana A. Bergamino (15038015)
Հրապարակվել է: (2025)

Supplementary Table S2 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
‌: Gia-Buu Tran (16437051)
Հրապարակվել է: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
‌: Nigel Bundred (15046233)
Հրապարակվել է: (2025)

Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures
‌: Vishwajith Sridharan (15047154)
Հրապարակվել է: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
‌: Alyssa C. Flint (16676029)
Հրապարակվել է: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
‌: Ulka N. Vaishampayan (15051039)
Հրապարակվել է: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
‌: Xufeng Lu (14960724)
Հրապարակվել է: (2025)

Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
‌: Sebastian Johannes Schober (14971891)
Հրապարակվել է: (2025)

Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
‌: Sebastian Johannes Schober (14971891)
Հրապարակվել է: (2025)

Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
‌: Sebastian Johannes Schober (14971891)
Հրապարակվել է: (2025)

Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
‌: Sebastian Johannes Schober (14971891)
Հրապարակվել է: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
‌: Carlotta Antoniotti (15352506)
Հրապարակվել է: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
‌: Santiago Duro-Sánchez (14959182)
Հրապարակվել է: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
‌: Alyssa C. Flint (16676029)
Հրապարակվել է: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
‌: Ulka N. Vaishampayan (15051039)
Հրապարակվել է: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
‌: Ulka N. Vaishampayan (15051039)
Հրապարակվել է: (2025)

Supplemental Figure S1 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
‌: Jennifer L. Cotton (17315204)
Հրապարակվել է: (2025)

Supplemental Figure S3 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
‌: Jennifer L. Cotton (17315204)
Հրապարակվել է: (2025)

Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
‌: Jennifer L. Cotton (17315204)
Հրապարակվել է: (2025)

Supplemental Figure S5 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
‌: Jennifer L. Cotton (17315204)
Հրապարակվել է: (2025)

Supplemental Figure S6 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
‌: Jennifer L. Cotton (17315204)
Հրապարակվել է: (2025)

Supplemental Figure S7 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
‌: Jennifer L. Cotton (17315204)
Հրապարակվել է: (2025)

Cannot write session to /tmp/vufind_sessions/sess_1od59k7tarm1sg98id4a21opup